C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Sign Up to like & getrecommendations! Published in 2020 at "Ophthalmology"
DOI: 10.1016/j.ophtha.2020.08.027
Abstract: PURPOSE The complement pathway may play a key role in the pathogenesis of age-related macular degeneration (AMD). The safety and efficacy of avacincaptad pegol (Zimura®), a C5 inhibitor, was assessed in participants with geographic atrophy… read more here.
Keywords: trial; age related; related macular; pegol ... See more keywords